About Us
Company Profile
Corporate Culture
Development
Organizational
Responsibility
Partners
Business Scope
CRO Services
Transformation Of Hospital Preparations
Registration Affairs
Medical Services
Cultivation Of Major TCM Varieties
SMO Service
Therapeutic Area
Breathe
Gynecology And Reproductive Medicine
Pediatrics
Tumor
Orthopedics
Cardiovascular And Cerebrovascular
Digestion
Endocrinology And Metabolism
Dermatology
Proctology
Urology
Neurological And Psychiatric Disorders
Qualification And Honor
Qualification And Honor
News
Company News
Industry News
Contact Us
EN
中文 EN
Company News
Industry News
Home - News and Information
Industry News
2026-06-24
2025 Drug Clinical Trial Volume Reaches New High, Offering New Treatment Options for Patients
The National Medical Products Administration (NMPA) released the 2025 Annual Report on the Progress of New Drug Registration Clinical Trials in China, reporting 5,215 clinical trial registrations for the year, surpassing 5,000 for the first time. Category I innovative drugs accounted for 72.4% of all new drug trials, with Phase I innovative drug trials ranking first globally. The report provides a comprehensive review of clinical trial data across multiple therapeutic areas, including anti-tumor drugs, weight-loss medications, cell and gene therapies, pediatric medicines, and rare disease drugs, while also offering insights into the current state of China’s original innovation capabilities in new drug R&D and the development of international multi-regional clinical trials.
Learn more
2026-02-28
The 2026 National Conference on Traditional Chinese Medicine Registration Administration and Quality Safety Supervision was held in Guangzhou.
The meeting was guided by Comrade Xi JinPing’s Thought on Socialism with Chinese Characteristics for a New Era, fully implemented the guiding principles from the 20th National Congress of the Communist Party of China and all previous plenary sessions of the 20th Central Committee, and carried out the requirements set forth at the national work conference on drug regulation. It reviewed the work accomplished in 2025 and during the 14th Five-Year Plan period, analyzed the current situation and challenges, and studied and planned the key tasks for 2026. Yang Sheng, Member of the Party Leadership Group and Deputy Commissioner of the National Medical Products Administration, attended the meeting and delivered a speech.
Learn more
1
2
Online Message

With a professional and efficient service system and a comprehensive operational network, Guangzhou Evidence Based Medicine is committed to providing tailored one-stop traditional Chinese medicine research and development full industry chain service solutions for every customer, promoting traditional Chinese medicine to the world and safeguarding the health of more people.

The business area you want to consult